Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

In honor of Rare Disease Day, here are 10 new treatments approved by the FDA to treat rare diseases over the past year.

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

MONTREAL, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) announced today that it has entered into a sale-leaseback transaction for its factory and warehousing facility in ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Ingram Micro Inc. (NYSE: INGM), a business-to-business (B2B) platform company for the global technology ecosystem, today announced its two partner communities?Ingram Micro SMB Alliance and Ingram ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025. Adjusted earnings per share (EPS) of $1.90 beat the Zacks Consensus Estimate ...

The market for Parkinson’s disease (PD) drugs across the seven major geographies (7MM; USA, France, Germany, Italy, UK and Japan) is projected to grow at a compound annual growth rate (CAGR) of 8.9% ...

52.2% of patients met the composite endpoint of the study. Seladelpar can result in clinically meaningful improvements in markers of cholestasis and liver injury in patients with primary biliary ...